Revolution Medicines Inc Aktie News

REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data for elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G12C non-small cell lung cancer (NSCLC) who had received ...

Biotech stocks Disc Medicine and Revolution Medicines jumped Friday after the duo received some of the first CNPVs.

REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted a non-transferrable voucher for daraxonrasib (RMC-6236), the company's RAS(ON) multi-selective inhibitor, under ...

REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan Sandler, M.D. into the newly created role of chief development officer, as well as the appointment of regional general managers in the U.S. and Europe.

Revolution Medicines, Inc. shares surged on strong Phase 1 data for daraxonrasib in metastatic pancreatic cancer, showing high response and disease control rates. Daraxonrasib demonstrated superior efficacy and durability versus current standards, with promising results in both monotherapy and combination with gemcitabine. RVMD secured a $2 billion deal with Royalty Pharma, ensuring robust fund...

Revolution Medicines, Inc. Metastatic Pancreatic Cancer Update Call September 10, 2025 5:00 PM EDT Company Participants Ryan Asay - Senior Vice President of Corporate Affairs Mark Goldsmith - CEO, President & Chairman Stephen Kelsey - President of Research & Development Wei Lin - Chief Medical Officer Conference Call Participants Albert Agustinus - Leerink Partners LLC, Research Division Michae...

Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Anthony Mancini - Chief Global Commercialization Officer Jack Anders - Chief Financial Officer Mark A. Goldsmith - CEO, President & Chairman Ryan Asay - Senior Vice President of Corporate Affairs Stephen M.